Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Astrocytoma

Astrocytoma

19

Pipeline Programs↗

17

Active Trials↗

15

Companies Involved↗

Astrocytoma is an emerging landscape with 19 programs across 15 companies. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

68/100

Attrition Rate

18/100

Pipeline

Programs by Phase

Preclinical5

Influenza Virus Vaccine

Sanofi

Mebendazole

Wim Janssens

Vincristine

Eli Lilly

Irinotecan

Pfizer

Procarbazine Hydrochloride

Leadiant Biosciences, Inc.

Phase 12

Mycophenolate Mofetil

Roche

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 28

Bevacizumab

Roche

Tuvusertib

EMD Serono Research & Development Institute, Inc.

Tislelizumab Plus Bevacizumab

Henan Provincial People's Hospital

Dabrafenib Mesylate

National Cancer Institute (NCI)

Trametinib Dimethyl Sulfoxide

Novartis

Phase 34

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vinblastine Sulfate

Eastern Cooperative Oncology Group

Selumetinib /m2

National Cancer Institute (NCI)

Trametinib

Novartis

Approved

No programs

Analysis

Modality Breakdown

82%

Small molecule

14 of 17 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 89% of 19 pipeline programs.

Analysis

Trial Status

51

clinical trials

Completed21 · 41%

Active, not recruiting9 · 18%

Terminated9 · 18%

Recruiting7 · 14%

Unknown status3 · 6%

Not yet recruiting1 · 2%

Other1 · 2%

Clinical Trials

Trial Activity

51 trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Recruiting·National Cancer Institute (NCI)·Phase 3·NCT04166409·170 enrolled

Vorasidenib as Maintenance Treatment After First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma: a Placebo-controlled, Triple-blind, Randomized Phase III Study (VIGOR)

Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT06809322·468 enrolled

A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06344130·28 enrolled

Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04623931·40 enrolled

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Recruiting·HHenry Ford Health System·Phase 1·NCT05686798·18 enrolled

Tuvusertib in Astrocytoma With ATRX Mutation

Recruiting·GGrupo Español de Investigación en Neurooncología·Phase 2·NCT07417761·56 enrolled

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recruiting·—·Phase 2·NCT06264388·33 enrolled

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

Active, not recruiting· Novartis logo

Novartis·Approved·NCT03975829·163 enrolled

A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma

Active, not recruiting·NNorthwestern University·Phase 1·NCT05236036·86 enrolled

A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT00268385·83 enrolled

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU

Active, not recruiting·MMayo Clinic·Phase 1·NCT04197934·56 enrolled

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Active, not recruiting·—·Preclinical·NCT01837862·10 enrolled

A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas

Active, not recruiting·NRG Oncology·Phase 2·NCT03180502·120 enrolled

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03581292·38 enrolled

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03919071·58 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)